当前位置：首页 SCI 期刊医学 Oncoimmunology(非官网)

OncoimmunologySCIE

国际简称：ONCOIMMUNOLOGY 参考译名：肿瘤免疫学

中科院分区
2区
CiteScore分区
Q1
JCR分区
Q1

基本信息：: ISSN：2162-402X; E-ISSN：2162-402X; 是否OA：未开放; 是否预警：否; TOP期刊：是

出版信息：: 出版地区：UNITED STATES; 出版商：Landes Bioscience; 出版语言：English; 出版周期：12 issues/year; 出版年份：2012; 研究方向：ONCOLOGYIMMUNOLOGY-IMMUNOLOGY

评价信息：: 影响因子：6.5; H-index：49; CiteScore指数：12.8; SJR指数：2.345; SNIP指数：0.987

发文数据：: Gold OA文章占比：100.00%; 研究类文章占比：96.49%; 年发文量：114; 自引率：0.0277...; 开源占比：0.9969; 出版撤稿占比：0; 出版国人文章占比：0.13; OA被引用占比：0.0951...

投稿咨询加急见刊

英文简介期刊介绍 CiteScore数据中科院SCI分区 JCR分区发文数据常见问题

英文简介Oncoimmunology期刊介绍

Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.

OncoImmunology will accept high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses will be welcome.

期刊简介Oncoimmunology期刊介绍

《Oncoimmunology》自2012出版以来，是一本医学优秀杂志。致力于发表原创科学研究结果，并为医学各个领域的原创研究提供一个展示平台，以促进医学领域的的进步。该刊鼓励先进的、清晰的阐述，从广泛的视角提供当前感兴趣的研究主题的新见解，或审查多年来某个重要领域的所有重要发展。该期刊特色在于及时报道医学领域的最新进展和新发现新突破等。该刊近一年未被列入预警期刊名单，目前已被权威数据库SCIE收录，得到了广泛的认可。

该期刊投稿重要关注点：

预计审稿时间： 24 Weeks
国际TOP期刊
医学
IMMUNOLOGY
SCIE
中科院2区
非预警

Cite Score数据（2024年最新版）Oncoimmunology Cite Score数据

CiteScore：12.8
SJR：2.345
SNIP：0.987

学科类别	分区	排名	百分位
大类：Medicine 小类：Oncology	Q1	40 / 404	90%
大类：Medicine 小类：Immunology and Allergy	Q1	30 / 233	87%
大类：Medicine 小类：Immunology	Q1	34 / 236	85%

CiteScore 是由Elsevier(爱思唯尔)推出的另一种评价期刊影响力的文献计量指标。反映出一家期刊近期发表论文的年篇均引用次数。CiteScore以Scopus数据库中收集的引文为基础，针对的是前四年发表的论文的引文。CiteScore的意义在于，它可以为学术界提供一种新的、更全面、更客观地评价期刊影响力的方法，而不仅仅是通过影响因子(IF)这一单一指标来评价。

历年Cite Score趋势图

中科院SCI分区Oncoimmunology 中科院分区

中科院 2023年12月升级版 综述期刊：否 Top期刊：否

大类学科	分区	小类学科	分区
医学	2区	IMMUNOLOGY 免疫学 ONCOLOGY 肿瘤学	2区 2区

中科院分区表 是以客观数据为基础，运用科学计量学方法对国际、国内学术期刊依据影响力进行等级划分的期刊评价标准。它为我国科研、教育机构的管理人员、科研工作者提供了一份评价国际学术期刊影响力的参考数据，得到了全国各地高校、科研机构的广泛认可。

中科院分区表 将所有期刊按照一定指标划分为1区、2区、3区、4区四个层次，类似于“优、良、及格”等。最开始，这个分区只是为了方便图书管理及图书情报领域的研究和期刊评估。之后中科院分区逐步发展成为了一种评价学术期刊质量的重要工具。

历年中科院分区趋势图

JCR分区Oncoimmunology JCR分区

2023-2024 年最新版

按JIF指标学科分区	收录子集	分区	排名	百分位
学科：IMMUNOLOGY	SCIE	Q1	30 / 181	83.7%
学科：ONCOLOGY	SCIE	Q1	44 / 322	86.5%

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：IMMUNOLOGY	SCIE	Q1	28 / 181	84.81%
学科：ONCOLOGY	SCIE	Q1	51 / 322	84.32%

JCR分区的优势在于它可以帮助读者对学术文献质量进行评估。不同学科的文章引用量可能存在较大的差异，此时单独依靠影响因子(IF)评价期刊的质量可能是存在一定问题的。因此，JCR将期刊按照学科门类和影响因子分为不同的分区，这样读者可以根据自己的研究领域和需求选择合适的期刊。

历年影响因子趋势图

发文数据

2023-2024 年国家/地区发文量统计

国家/地区数量
USA325
CHINA MAINLAND199
France160
GERMANY (FED REP GER)133
Sweden83
Italy63
Netherlands58
Canada51
England46
Switzerland38

本刊中国学者近年发表论文

1、M2 macrophage-derived exosomes suppress tumor intrinsic immunogenicity to confer immunotherapy resistance
Author: Zheng, Naisheng; Wang, Tingting; Luo, Qin; Liu, Yi; Yang, Junyao; Zhou, Yunlan; Xie, Guohua; Ma, Yanhui; Yuan, Xiangliang; Shen, Lisong

Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2023.2210959
2、Expression of OLR1 gene on tumor-associated macrophages of head and neck squamous cell carcinoma, and its correlation with clinical outcome
Author: Zhang, Peng; Zhao, Yan; Xia, Xin; Mei, Song; Huang, Yixuan; Zhu, Yingying; Yu, Shuting; Chen, Xingming

Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2023.2203073
3、Altered phenotypic and metabolic characteristics of FOXP3(+)CD3(+)CD56(+) natural killer T (NKT)-like cells in human malignant pleural effusion
Author: Wang, Zi-Hao; Zhang, Pei; Peng, Wen-Bei; Ye, Lin-Lin; Xiang, Xuan; Wei, Xiao-Shan; Niu, Yi-Ran; Zhang, Si-Yu; Xue, Qian-Qian; Wang, Hao-Lei; Zhou, Qiong

Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2022.2160558
4、Prognostic and predictive value of Immunoscore and its correlation with ctDNA in stage II colorectal cancer
Author: Wang, Fulong; Lu, Shixun; Cao, Di; Qian, Juanjuan; Li, Cong; Zhang, Rongxin; Wang, Feng; Wu, Miaoqing; Liu, Yifan; Pan, Zhizhong; Wu, Xiaojun; Lu, Zhenhai; Ding, Peirong; Li, Liren; Lin, Junzhong; Catteau, Aurelie; Galon, Jerome; Chen, Gong

Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2022.2161167
5、CARD9 deficiency promotes pancreatic cancer growth by blocking dendritic cell maturation via SLC6A8-mediated creatine transport
Author: Tian, Cheng; Yuan, Huimin; Lu, Yi; He, Henghui; Li, Qing; Li, Senlin; Yang, Jian; Wang, Mengheng; Xu, Ruochen; Liu, Qian; Xiang, Ming

Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2023.2204015
6、Gankyrin-mediated interaction between cancer cells and tumor-associated macrophages facilitates prostate cancer progression and androgen deprivation therapy resistance
Author: Peng, Guang; Wang, Chao; Wang, Hongru; Qu, Min; Dong, Keqin; Yu, Yongwei; Jiang, Yuquan; Gan, Sishun; Gao, Xu

Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2023.2173422
7、Suppression of prostate cancer and amelioration of the immunosuppressive tumor microenvironment through selective immunoproteasome inhibition
Author: Koerner, Julia; Horvath, Dennis; Oliveri, Franziska; Li, Jun; Basler, Michael

Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2022.2156091
8、Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles
Author: Deng, Jun; Ke, Hui

Journal: ONCOIMMUNOLOGY. 2023; Vol. 12, Issue 1, pp. -. DOI: 10.1080/2162402X.2022.2152635